BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23686610)

  • 1. Measuring activity in the ubiquitin-proteasome system: from large scale discoveries to single cells analysis.
    Melvin AT; Woss GS; Park JH; Waters ML; Allbritton NL
    Cell Biochem Biophys; 2013 Sep; 67(1):75-89. PubMed ID: 23686610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitination and deubiquitination: Implications on cancer therapy.
    Dagar G; Kumar R; Yadav KK; Singh M; Pandita TK
    Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194979. PubMed ID: 37633647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timer-based proteomic profiling of the ubiquitin-proteasome system reveals a substrate receptor of the GID ubiquitin ligase.
    Kong KE; Fischer B; Meurer M; Kats I; Li Z; Rühle F; Barry JD; Kirrmaier D; Chevyreva V; San Luis BJ; Costanzo M; Huber W; Andrews BJ; Boone C; Knop M; Khmelinskii A
    Mol Cell; 2021 Jun; 81(11):2460-2476.e11. PubMed ID: 33974913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the ubiquitin proteasome system in hematologic malignancies.
    Sahasrabuddhe AA; Elenitoba-Johnson KS
    Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A patent review of the ubiquitin ligase system: 2015-2018.
    Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
    Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of the ubiquitination kinetics of multiple degrons to identify an ideal targeting sequence for a proteasome reporter.
    Melvin AT; Woss GS; Park JH; Dumberger LD; Waters ML; Allbritton NL
    PLoS One; 2013; 8(10):e78082. PubMed ID: 24205101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.
    Guharoy M; Bhowmick P; Tompa P
    J Biol Chem; 2016 Mar; 291(13):6723-31. PubMed ID: 26851277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome substrate receptors and their therapeutic potential.
    Osei-Amponsa V; Walters KJ
    Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescent reporters for the ubiquitin-proteasome system.
    Salomons FA; Verhoef LG; Dantuma NP
    Essays Biochem; 2005; 41():113-28. PubMed ID: 16250901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro autoubiquitination activity of E3 ubiquitin ligases of the N-degron pathway.
    Sandmann A; Dissmeyer N
    Methods Enzymol; 2023; 686():205-220. PubMed ID: 37532400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin proteasome system in immune regulation and therapeutics.
    Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
    Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.
    Liu J; Zheng H; Tang M; Ryu YC; Wang X
    Am J Physiol Heart Circ Physiol; 2008 Dec; 295(6):H2541-50. PubMed ID: 18978187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic pathways controlled by E3 ligases: an opportunity for therapeutic targeting].
    Taillandier D
    Biol Aujourdhui; 2021; 215(1-2):45-57. PubMed ID: 34397374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of proteasome reveals basal mitochondrial ubiquitination.
    Sulkshane P; Duek I; Ram J; Thakur A; Reis N; Ziv T; Glickman MH
    J Proteomics; 2020 Oct; 229():103949. PubMed ID: 32882436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.
    Nguyen HC; Wang W; Xiong Y
    Subcell Biochem; 2017; 83():323-347. PubMed ID: 28271482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin-Proteasome Pathway and Muscle Atrophy.
    Khalil R
    Adv Exp Med Biol; 2018; 1088():235-248. PubMed ID: 30390254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin.
    Lin L; Jin Z; Tan H; Xu Q; Peng T; Li H
    Brain Res; 2016 Jul; 1643():103-12. PubMed ID: 27107943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
    Poirson J; Biquand E; Straub ML; Cassonnet P; Nominé Y; Jones L; van der Werf S; Travé G; Zanier K; Jacob Y; Demeret C; Masson M
    FEBS J; 2017 Oct; 284(19):3171-3201. PubMed ID: 28786561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy.
    Goru SK; Kadakol A; Gaikwad AB
    Pharmacol Res; 2017 Jun; 120():170-179. PubMed ID: 28363724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the ubiquitin-proteasome system in brain ischemia: friend or foe?
    Caldeira MV; Salazar IL; Curcio M; Canzoniero LM; Duarte CB
    Prog Neurobiol; 2014 Jan; 112():50-69. PubMed ID: 24157661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.